93 related articles for article (PubMed ID: 22430898)
1. Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression.
Spears M; Cunningham CA; Taylor KJ; Mallon EA; Thomas JS; Kerr GR; Jack WJ; Kunkler IH; Cameron DA; Chetty U; Bartlett JM
J Pathol; 2012 Aug; 227(4):481-9. PubMed ID: 22430898
[TBL] [Abstract][Full Text] [Related]
2. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.
Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
Eur J Cancer; 2013 Apr; 49(6):1196-204. PubMed ID: 23305873
[TBL] [Abstract][Full Text] [Related]
3. Akt isoform-specific inhibition of MDA-MB-231 cell proliferation.
Yang W; Ju JH; Lee KM; Shin I
Cell Signal; 2011 Jan; 23(1):19-26. PubMed ID: 20688159
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.
Héron-Milhavet L; Franckhauser C; Rana V; Berthenet C; Fisher D; Hemmings BA; Fernandez A; Lamb NJ
Mol Cell Biol; 2006 Nov; 26(22):8267-80. PubMed ID: 16982699
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.
Gershtein ES; Scherbakov AM; Shatskaya VA; Kushlinsky NE; Krasil'nikov MA
Anticancer Res; 2007; 27(4A):1777-82. PubMed ID: 17649772
[TBL] [Abstract][Full Text] [Related]
7. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
8. Significance of Akt activation and AKT gene increases in soft tissue tumors.
Dobashi Y; Sato E; Oda Y; Inazawa J; Ooi A
Hum Pathol; 2014 Jan; 45(1):127-36. PubMed ID: 24321521
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
10. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations in AKT and its protein activation in human lung carcinomas.
Dobashi Y; Kimura M; Matsubara H; Endo S; Inazawa J; Ooi A
Hum Pathol; 2012 Dec; 43(12):2229-40. PubMed ID: 22748472
[TBL] [Abstract][Full Text] [Related]
12. Distinct functions of AKT isoforms in breast cancer: a comprehensive review.
Hinz N; Jücker M
Cell Commun Signal; 2019 Nov; 17(1):154. PubMed ID: 31752925
[TBL] [Abstract][Full Text] [Related]
13. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Riggio M; Perrone MC; Polo ML; Rodriguez MJ; May M; Abba M; Lanari C; Novaro V
Sci Rep; 2017 Mar; 7():44244. PubMed ID: 28287129
[TBL] [Abstract][Full Text] [Related]
14. Akt2, but not Akt1, is required for cell survival by inhibiting activation of JNK and p38 after UV irradiation.
Kim MA; Kim HJ; Jee HJ; Kim AJ; Bae YS; Bae SS; Yun J
Oncogene; 2009 Mar; 28(9):1241-7. PubMed ID: 19151757
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
16. Differential activation of CREB by Akt1 and Akt2.
Kato S; Ding J; Du K
Biochem Biophys Res Commun; 2007 Mar; 354(4):1061-6. PubMed ID: 17276404
[TBL] [Abstract][Full Text] [Related]
17. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
[TBL] [Abstract][Full Text] [Related]
19. Reduction of Akt2 expression inhibits chemotaxis signal transduction in human breast cancer cells.
Wang J; Wan W; Sun R; Liu Y; Sun X; Ma D; Zhang N
Cell Signal; 2008 Jun; 20(6):1025-34. PubMed ID: 18353613
[TBL] [Abstract][Full Text] [Related]
20. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion.
Wang S; Basson MD
Exp Cell Res; 2008 Jan; 314(2):286-96. PubMed ID: 17825284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
